Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body

Area of Science:

• Pharmacokinetics
• Oncology
• Computational Biology

Background:

• Colorectal cancer is a leading cause of death, with irinotecan as a key treatment.
• Irinotecan's efficacy is limited by adverse effects and significant pharmacokinetic variability.
• Physiologically based pharmacokinetic (PBPK) models can predict drug behavior.

Purpose of the Study:

• To develop and evaluate a whole-body PBPK (WB-PBPK) model for irinotecan in cancer patients.
• To depict the concentration of irinotecan and its active metabolite over time.
• To extract and validate pharmacokinetic parameters using clinical data.

Main Methods:

• Utilized WB-PBPK technology to create a model for patients receiving intravenous irinotecan.
• Simulated drug and metabolite concentrations within the human body.
• Validated the model against observed clinical study results from literature.

Main Results:

• The WB-PBPK model successfully depicted irinotecan and metabolite concentrations.
• Predicted pharmacokinetic parameters showed good agreement with observed clinical data.
• The model demonstrates reliability for predicting irinotecan behavior.

Conclusions:

• WB-PBPK modeling is a valuable tool for understanding irinotecan pharmacokinetics in cancer patients.
• This approach can aid in optimizing irinotecan therapy, especially in patients with comorbidities.
• Further exploration of irinotecan PK in complex patient populations is supported.